Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corporation (NASDAQ: DXR) is a medical instrumentation and biotechnology company focused on blood volume measurement, and its news flow centers on developments in this specialized diagnostic area. The company describes itself as the global leader in blood volume measurement technology, with approximately 50 years of experience and a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic platform.
News about Daxor frequently highlights regulatory milestones, such as FDA 510(k) clearance for its next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer (Daxor BVA™). Announcements also cover commercial expansion, including adoption of its BVA platform and ezBVA Lab Service by health systems, academic medical centers and cardiology practices, as well as deployments of on-site analyzers for immediate blood volume assessment.
Investors and clinicians following DXR can expect updates on clinical research that evaluates BVA-guided care in conditions like heart failure, LVAD implantation, cardiac amyloidosis, sepsis and COVID-19. Company releases summarize peer-reviewed studies and pilot trials that examine outcomes such as readmissions, survival, kidney injury and hospital length of stay when blood volume analysis is incorporated into care pathways.
Daxor’s news flow also includes participation in medical and investor conferences, where management presents corporate updates and showcases its technology to cardiovascular and critical care audiences, as well as institutional investors. For those tracking DXR, this news page offers a focused view of how the company’s blood volume analysis technology is progressing through regulatory clearance, clinical validation and market adoption over time.
Daxor Corporation (Nasdaq: DXR) has presented new data at the ISHLT Annual Meeting showcasing the efficacy of its BVA-100 blood test in enhancing survival rates for advanced heart failure patients using LVADs. The study revealed that 91% of patients with LVADs exhibited abnormal blood volume, indicating the test's critical role in patient management. With a 98% accuracy rate, the BVA-100 test helps identify derangements in blood volume, potentially improving patient outcomes. Daxor emphasizes its commitment to advancing healthcare through blood volume analysis technology.
Daxor Corporation (Nasdaq: DXR) presented new data from a study at the 71st American College of Cardiology meeting on April 2, revealing the effectiveness of the BVA-100 test in measuring intravascular congestion in heart failure patients. This test outperformed common clinical tools, which were found ineffective. The study led by Dr. Vishal N. Rao emphasized that blood volume measurements do not correlate with cardiac pressures, indicating the superiority of Daxor's approach in improving patient outcomes in heart failure management.
Daxor Corporation (Nasdaq: DXR) announced that CEO Michael Feldschuh will present at the Maxim Group 2022 Virtual Growth Conference from March 28-30, 2022. The presentation will cover recent achievements, including contracts with the U.S. Department of Defense, NIH grant funding, and clinical trials for its BVA-100® blood test aimed at critical care management, COVID-19, and heart failure. Registration is required to attend the conference and view the presentation.
Daxor Corporation (Nasdaq: DXR) reported significant achievements in its recent shareholder update. On February 4, 2022, Daxor celebrated its Nasdaq listing with a ceremonial bell ringing in Times Square. The company achieved a 70.6% revenue increase in 2021 compared to the previous year, reporting a net asset value of $21.15 million. Daxor plans to launch new point-of-care blood volume systems in 2022, enhancing market capabilities. The company also made strides in clinical outcomes and research with NIH support, marking a pivotal year for growth and innovation.
Daxor Corporation (Nasdaq: DXR) reported impressive financial results for fiscal 2021, achieving a 70.6% increase in unaudited revenues from its operating division, which includes the BVA diagnostic systems. The company's net asset value (NAV) rose to $5.24 per share, marking a 34.7% increase from $3.89 in 2020. The growth is attributed to new client contracts, including the U.S. Department of Defense. Daxor also announced advancements in its next-generation blood volume analysis technology and secured a $750,000 contract for further development.
Daxor Corporation (Nasdaq: DXR) has revealed new data on the clinical utility of its BVA-100 blood test for heart failure patients, published in the Journal of Cardiac Failure. The study indicates a disconnect between pressure and blood volume metrics, emphasizing the importance of blood volume assessment over pressure monitoring in managing heart failure. Authors noted that volume-based strategies may enhance patient care. With over 100 peer-reviewed studies supporting its efficacy, Daxor's technology is positioned as a critical tool in addressing heart volume management.
Daxor Corporation (Nasdaq: DXR) commenced trading on the NASDAQ Capital Markets on February 2, 2022. To celebrate, CEO Michael Feldschuh will ring the Opening Bell on February 4, 2022. This milestone is expected to enhance the company's visibility, trading liquidity, and attract institutional investors. Daxor specializes in blood volume measurement technology, with over 60,000 tests conducted using their FDA-cleared BVA-100. Ongoing trials in heart failure and COVID-19 are supported by the NIH and the Department of Defense.
Daxor Corporation (NYSE: DXR) has appointed Caleb DesRosiers to its Board of Directors, effective January 18, 2022. DesRosiers, a Senior Principal at Valuate Healthcare Consultancy, brings extensive strategic and regulatory experience to the role, having previously worked with CMS and in the life sciences sector at Pfizer and Roche. CEO Michael Feldschuh expressed that DesRosiers' expertise will support Daxor's vision of optimal blood volume for patients. Daxor is a leader in blood volume measurement technology with its FDA-cleared BVA-100 Blood Volume Analyzer.
Daxor Corporation (NYSE: DXR) has announced the transfer of its common stock listing from the New York Stock Exchange - American to The Nasdaq Capital Market, effective February 2, 2022. CEO Michael Feldschuh stated that this move is expected to enhance stock visibility, trading liquidity, and attract institutional investors. Daxor is recognized for its BVA-100® technology, the first FDA-cleared diagnostic blood test for quantifying blood volume. The company aims to advance healthcare through optimal fluid management.
Oak Ridge, TN, Jan. 06, 2022 - Daxor, the leader in blood volume measurement technology, announced that CEO Michael Feldschuh will present at the H.C. Wainwright BioConnect 2022 Virtual Conference from January 10-13, 2022. The presentation will be available on-demand starting at 7:00 a.m. ET on January 10. Key highlights will include updates on the new patent award and development of BVA-100. Daxor aims to improve healthcare through advanced blood volume analysis, focusing on enhancing treatment strategies in various medical fields.